Drug Profile
E 13R
Alternative Names: E13RLatest Information Update: 28 May 2007
Price :
$50
*
At a glance
- Originator BresaGen
- Class Antiasthmatics
- Mechanism of Action Interleukin 5 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 28 Feb 2003 E 13R is available for licensing (http://www.bresagen.com.au)
- 28 Feb 2003 Suspended - Preclinical for Asthma in Australia (unspecified route)
- 11 Jul 2001 Preclinical development for Asthma in Australia (Unknown route)